Circuit Clinical announced a collaboration with Roswell Park Comprehensive Cancer Center to support the expansion of clinical trial opportunities to its outpatient oncology practices. This collaboration marks Circuit Clinical's entry into oncology clinical research, with both digital and clinical services.
FDA approved pembrolizumab (Keytruda) for the first-line treatment of patients with stage III non-small cell lung cancer who are not candidates for surgical resection or definitive chemoradiation or metastatic NSCLC. Patients' tumors must have no EGFR or ALK genomic aberrations and express PD-L1 (Tumor Proportion Score ≥1%) determined by an FDA-approved test.
AstraZeneca and Merck announced the European Commission has approved Lynparza as a monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, and who have HER2-negative locally advanced or metastatic breast cancer.
FDA has approved a labeling change for Soltamox (tamoxifen citrate, oral solution), reverting to two months of contraception following cessation of tamoxifen.
Some patients who died within one month of being newly diagnosed with metastatic cancer in the United States received ineffective surgery, chemotherapy, radiation, and hormonal therapy according to a new American Cancer Society study.
The number of electronic health record systems joining with CancerLinQ to facilitate information sharing continues to grow. CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology, announced Varian's ARIA Oncology Information System is the next Electronic Health Record System to be certified by CancerLinQ after meeting criteria for interoperability and data standardization. This collaboration aims to dismantle barriers to information sharing and streamline access to CancerLinQ for oncology practices using Varian ARIA OIS.
FDA is extending the indication of Ibrance (palbociclib) capsules in combination with specific endocrine therapies for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in male patients.
FDA issued a warning letter to Inova Genomics Laboratory of Falls Church, Virginia, for illegally marketing certain genetic tests that have not been reviewed by the FDA for safety and effectiveness. The tests claim to predict patients' responses to specific medications based on genetic variants.
Nanobiotix announced Hensify (NBTXR3) has obtained a CE mark for the treatment of locally-advanced soft tissue sarcoma. Hensify is the brand name for NBTXR3 as approved for the treatment of locally-advanced STS.
Bristol-Myers Squibb Co. announced results from pooled analyses of survival data from four studies (CheckMate -017, -057, -063 and -003; n=664) in patients with previously-treated advanced non-small cell lung cancer who were treated with Opdivo (nivolumab).
